PDS Biotechnology EBITDA vs. Shares Owned By Insiders
| PDSB Stock | USD 1.65 0.10 5.71% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -40.1 M | Current Value -42.1 M | Quarterly Volatility 15.6 M |
For PDS Biotechnology profitability analysis, we use financial ratios and fundamental drivers that measure the ability of PDS Biotechnology to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well PDS Biotechnology Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between PDS Biotechnology's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of PDS Biotechnology Corp over time as well as its relative position and ranking within its peers.
PDS |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PDS Biotechnology. If investors know PDS will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PDS Biotechnology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.17) | Return On Assets (0.40) | Return On Equity (1.28) |
The market value of PDS Biotechnology Corp is measured differently than its book value, which is the value of PDS that is recorded on the company's balance sheet. Investors also form their own opinion of PDS Biotechnology's value that differs from its market value or its book value, called intrinsic value, which is PDS Biotechnology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PDS Biotechnology's market value can be influenced by many factors that don't directly affect PDS Biotechnology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PDS Biotechnology's value and its price as these two are different measures arrived at by different means. Investors typically determine if PDS Biotechnology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PDS Biotechnology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
PDS Biotechnology Corp Shares Owned By Insiders vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining PDS Biotechnology's current stock value. Our valuation model uses many indicators to compare PDS Biotechnology value to that of its competitors to determine the firm's financial worth. PDS Biotechnology Corp is rated below average in ebitda category among its peers. It also is rated below average in shares owned by insiders category among its peers . At present, PDS Biotechnology's EBITDA is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PDS Biotechnology's earnings, one of the primary drivers of an investment's value.PDS Shares Owned By Insiders vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
PDS Biotechnology |
| = | (40.08 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.
PDS Biotechnology |
| = | 3.99 % |
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
PDS Shares Owned By Insiders Comparison
PDS Biotechnology is currently under evaluation in shares owned by insiders category among its peers.
PDS Biotechnology Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in PDS Biotechnology, profitability is also one of the essential criteria for including it into their portfolios because, without profit, PDS Biotechnology will eventually generate negative long term returns. The profitability progress is the general direction of PDS Biotechnology's change in net profit over the period of time. It can combine multiple indicators of PDS Biotechnology, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -43 M | -45.2 M | |
| Income Before Tax | -44.3 M | -46.6 M | |
| Total Other Income Expense Net | -1.3 M | -1.2 M | |
| Net Loss | -42.9 M | -45.1 M | |
| Income Tax Expense | -1.4 M | -1.5 M | |
| Interest Income | 2.8 M | 3 M | |
| Net Loss | -36.8 M | -34.9 M | |
| Net Interest Income | -1.1 M | -1.2 M | |
| Net Loss | -51.2 M | -53.7 M | |
| Non Operating Income Net Other | 49.5 K | 44 K | |
| Change To Netincome | 6 M | 6.3 M | |
| Net Loss | (1.39) | (1.46) | |
| Income Quality | 0.78 | 0.75 | |
| Net Income Per E B T | 0.97 | 1.03 |
PDS Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on PDS Biotechnology. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of PDS Biotechnology position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the PDS Biotechnology's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in PDS Biotechnology without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Theme Ratings Now
Theme RatingsDetermine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
| All Next | Launch Module |
Use Investing Themes to Complement your PDS Biotechnology position
In addition to having PDS Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Energy Funds Thematic Idea Now
Energy Funds
Funds or Etfs investing in energy sector, natural resources, and ecology. The Energy Funds theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Energy Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Your Equity Center. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
To fully project PDS Biotechnology's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of PDS Biotechnology Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include PDS Biotechnology's income statement, its balance sheet, and the statement of cash flows.